InvestorsHub Logo
Followers 0
Posts 1151
Boards Moderated 0
Alias Born 07/10/2003

Re: None

Sunday, 08/01/2004 6:32:45 AM

Sunday, August 01, 2004 6:32:45 AM

Post# of 82595
WGCU interview with Tony Frudakis from 19th July 2004

http://www.wgcu.org/listen/gulfcoast_live.asp

Some highlights:

They are not developing drugs yet but intend to.

The error rate of DNAWitness is 4-8% for any percentage measured.

They will use facial recognition software in conjunction with DNA Witness to construct digital sketches of suspects. Future traits to be covered by DNA Witness:

- Skin color
- Eye color
- Hair color
- Height
- Weight
- Nose shape
- Distance between eyes
- Distance between cheekbones
- Whether earlobes attached
- Longitude and latitude of face
- Depth of cranium
- Any unusual inherited traits e.g. skull shape

The interviewer referred to a paper that Tony has apparently written called "Pharmacogenomics: The Paradigm Shift". Not sure if, when, or in what journal this is to be published.

When asked about cardiac drug related classifier development, Tony mentioned that DNAP had concentrated on a number of types of drugs, and specifically mentioned ace inhibitors and statins.

When asked about ovarian cancer/chemotherapy confirmed that can predict taxol and carboplatin response (based on two genes) and said that they are in the later stages of validating ovanome and "discussing with various types of organizations mechanisms of getting this type of test used and accepted for compensation by insurance companies, etc."

Have a nice day all.